Revelation Biosciences, Inc. SEC filings REVB
Revelation Biosciences, Inc. has 389 filings in SEC EDGAR's recent list, going back to May 14, 2020. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended May 11, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | May 11, 2026 | Jun 24, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 30, 2026 | Jun 24, 2026 |
| DEF 14A | Proxy statement | Feb 17, 2026 | Feb 14, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 6, 2026 | Feb 6, 2026 |
| DEF 14A | Proxy statement | Nov 10, 2025 | Dec 3, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 30, 2025 | Oct 30, 2025 |
| DEF 14A | Proxy statement | Sep 22, 2025 | Sep 22, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 12, 2025 | Sep 11, 2025 |
| DEF 14A | Proxy statement | Jun 9, 2025 | May 29, 2025 |
| PRE 14A | Preliminary proxy statement | May 29, 2025 | May 28, 2025 |
| DEFA14A | Additional proxy material | Jan 13, 2025 | — |
| DEF 14A | Proxy statement | Dec 16, 2024 | Dec 13, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 5, 2024 | Dec 3, 2024 |
| DEF 14A | Proxy statement | Apr 16, 2024 | Apr 15, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2024 | Apr 5, 2024 |
| DEF 14A | Proxy statement | Dec 22, 2023 | Dec 22, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 12, 2023 | Dec 12, 2023 |
| DEFA14A | Additional proxy material | Jul 7, 2023 | — |
| DEFA14A | Additional proxy material | Jun 15, 2023 | — |
| DEF 14A | Proxy statement | May 5, 2023 | May 5, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2023 | Apr 25, 2023 |
| DEFA14A | Additional proxy material | Jan 13, 2023 | — |
| DEF 14A | Proxy statement | Dec 30, 2022 | Jan 20, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 20, 2022 | Dec 20, 2023 |
| DEFA14A | Additional proxy material | Dec 17, 2021 | — |
| DEFA14A | Additional proxy material | Nov 24, 2021 | — |
| DEF 14A | Proxy statement | Sep 21, 2021 | Oct 8, 2021 |
| PRE 14A | Preliminary proxy statement | Sep 7, 2021 | Sep 3, 2021 |
| DEFA14A | Additional proxy material | Aug 31, 2021 | — |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REVB (Nasdaq), REVBW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810560
- Former names
- Petra Acquisition Inc. (until Jan 11, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.